Search

Your search keyword '"Thomas M. Grogan"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Thomas M. Grogan" Remove constraint Author: "Thomas M. Grogan" Journal blood Remove constraint Journal: blood
33 results on '"Thomas M. Grogan"'

Search Results

1. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma

2. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

3. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction

4. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

5. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

6. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features

7. Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non-Hodgkin’s Lymphomas

8. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia

9. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study

10. P-glycoprotein expression and function in circulating blood cells from normal volunteers

11. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy

12. Long-term engraftment of fresh human myeloma cells in SCID mice

13. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement [see comments]

14. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer

15. Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19)

16. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms

17. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

18. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

19. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

20. Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP

21. Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL)

22. Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line

23. Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma

24. High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA

25. Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800)

26. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features

27. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation

28. CALLA-positive myeloma: an aggressive subtype with poor survival

29. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype

30. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67

31. Establishment of two new myeloma cell lines from bilateral pleural effusions: evidence for sequential in vivo clonal change

32. Myelomonocytic myeloma cell line (LB 84-1)

33. Myelomonocytic antigen positive multiple myeloma

Catalog

Books, media, physical & digital resources